Over USD 20 billion in partnering
transactions have been concluded each year
for the past four years in biotech with sometimes
dramatic results for both major pharmaceutical companies
and smaller biotechs. EBD Group believes the coming
years will see dealmaking rise significantly from
the current plateau to achieve extraordinary new levels.
The Next-Big-Thing . . . Is Not A Drug, predicts BioWorld, the daily journal tracking trends in the biotechnology and pharmaceutical markets. While drugs continue to dominate conversation, a transaction trend is driving a converging industry that is "abuzz with news of deals," says BioWorld.
"Online collaboration is
the future," said Carola Schropp, President
of EBD Group. "The next stage of service at EBD Group
is to create anytime, anywhere partnering across the
globe to accelerate relationships."